Hormonal
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) induce significant weight loss and metabolic improvement in patients with Bardet-Biedl syndrome (BBS), a genetic obesity syndrome previously resistant to standard pharmacotherapy.
If you have Bardet-Biedl Syndrome and struggle with severe obesity despite trying other medications, GLP-1 receptor agonists (like semaglutide or liraglutide) combined with dietary changes may be a viable treatment option. This case showed a 33% weight loss and normalized blood sugar, suggesting that genetic obesity is not necessarily resistant to these specific hormonal therapies.
We report a patient with BBS who underwent successful weight reduction through the use of glucagon-like peptide-1 receptor agonists.
Why this rating
Evidence is based on a single case report (n=1), lacking statistical power or control groups.
Source
Weight loss with glucagon‐like peptide‐1 receptor agonists in <scp>Bardet‐Biedl</scp> syndrome
Shawg Ganawa et al. · Clinical Obesity · 2022
DOI 10.1111/cob.12546
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →